Neuralstem Receives Approval To Commence First ALS Stem Cell Trial At Emory ALS Center

December 23, 2009

Neuralstem, Inc. (NYSE Amex: CUR) announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center, under the direction of Dr. Jonathan Glass M.D., Director of the Emory ALS Center, who will serve as the site Principal Investigator (PI).

To read the full story, click on the following link:

http://www.medicalnewstoday.com/articles/174522.php

Advertisements

2 Responses to “Neuralstem Receives Approval To Commence First ALS Stem Cell Trial At Emory ALS Center”

  1. Anthony said

    Hi Rich. This looks like a promising technology. Is the enrollment open for you to apply to participate?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: